{
  "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
  "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 57,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 25,
  "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/24",
  "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
  "deckJsonHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3.json",
  "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "callout",
      "text": "14,982 patient annual incidence",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94a13367-bd21-4e9c-ad66-92678c22d01d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Birtamimab Source: Gertz MA et al. First-in-Human Phase I/II Study of NEOD001... (full citation text)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aea4be14-cafd-485a-b50c-783155737f5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.94,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "table",
      "text": "Comparison table of NXC-201 vs Darzalex, Investigator's Choice, CAEL-101, and Birtamimab across various clinical metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "febc9748-90b2-4544-9cbb-8fc559c23326",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in AL (light chain) Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72010ccb-62f0-4445-ba8c-196825595a08",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "5175282f-6926-41e5-a493-a2ddcef3e734",
      "evidence": "Structured data comparing NXC-201 against competitors across multiple clinical metrics.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 23,
      "beatId": "71e54a80-3feb-4065-9889-e8bc30f294b6",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The clinical highlights and proportion of patients with sCR/CR slides create desire for the solution.",
      "position": 5,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}